Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

Eyre TA, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, Cross M, Forconi F, Shah N, Chasty R, Hart A, Broom A, Marr H, Patten PEM, Dann A, Arumainathan A, Munir T, Shankara P, Bloor A, Johnston R, Orchard K, Schuh AH, Fox CP; the UK CLL Forum.

Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15802. [Epub ahead of print]

PMID:
30768675
2.

Complete remission of immunochemotherapy-refractory monomorphic post-transplant lymphoproliferative disorder mediated by endogenous T-cell recovery.

Bishton MJ, Long HM, Dowell AC, Meckiff BJ, Byrne C, Fox CP.

Leuk Lymphoma. 2019 Feb 5:1-4. doi: 10.1080/10428194.2019.1571203. [Epub ahead of print] No abstract available.

PMID:
30721640
3.

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP.

Br J Haematol. 2018 Dec 13. doi: 10.1111/bjh.15722. [Epub ahead of print]

PMID:
30548597
4.

Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.

Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P, Cwynarski K; British Society for Haematology.

Br J Haematol. 2019 Feb;184(3):348-363. doi: 10.1111/bjh.15661. Epub 2018 Nov 23. No abstract available.

PMID:
30467845
5.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP.

Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6. No abstract available.

6.

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.

Schuh AH, Parry-Jones N, Appleby N, Bloor A, Dearden CE, Fegan C, Follows G, Fox CP, Iyengar S, Kennedy B, McCarthy H, Parry HM, Patten P, Pettitt AR, Ringshausen I, Walewska R, Hillmen P.

Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460. [Epub ahead of print] No abstract available.

PMID:
30009455
7.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.

Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari ME, Schaap M, Fox CP, Kröger N, Montoto S, Schetelig J.

Bone Marrow Transplant. 2018 May 4. doi: 10.1038/s41409-018-0207-4. [Epub ahead of print]

PMID:
29728701
8.

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE.

JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604.

9.

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

Eyre TA, Fox CP, Boden A, Bloor A, Dungawalla M, Shankara P, Went R, Schuh AH.

Br J Haematol. 2019 Feb;184(4):667-671. doi: 10.1111/bjh.15151. Epub 2018 Feb 22. No abstract available.

PMID:
29468637
10.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.

PMID:
29054815
11.

High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.

Kassam S, Chernucha E, O'Neill A, Hemmaway C, Cummins T, Montoto S, Lennard A, Adams G, Linton K, McKay P, Davies D, Rowntree C, Easdale S, Eyre TA, Marcus R, Cwynarski K, Fox CP.

Bone Marrow Transplant. 2017 Sep;52(9):1268-1272. doi: 10.1038/bmt.2017.101. Epub 2017 Jun 5.

PMID:
28581466
12.

A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.

Bagot M, Hasan B, Whittaker S, Beylot-Barry M, Knobler R, Shah E, Marreaud S, Morris S, Dalle S, Servitje O, Cowan R, Väkevä L, Chaby G, Jonak C, Fox CP, Ritchie D, Vermeer MH, Stadler R, Romero PLO, Scarisbrick J, Quaglino P.

Eur J Dermatol. 2017 Jun 1;27(3):286-294. doi: 10.1684/ejd.2017.3008.

PMID:
28468739
13.

High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.

Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O, De-Silva D, Cwynarski K, Houillier C, Hoang-Xuan K, Touitou V, Cassoux N, Marolleau JP, Tamburini J, Houot R, Delwail V, Illerhaus G, Soussain C, Kasenda B.

Bone Marrow Transplant. 2017 Aug;52(8):1113-1119. doi: 10.1038/bmt.2017.23. Epub 2017 Apr 24.

14.

Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate.

Munir T, Bishton MJ, Carter I, McMillan A, O'Connor S, Sovani V, Haynes AP, Fox CP.

Clin Lymphoma Myeloma Leuk. 2016 Dec;16(12):705-712. doi: 10.1016/j.clml.2016.08.014. Epub 2016 Aug 10.

PMID:
27640075
15.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
16.

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, Ljungman P; Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).

Haematologica. 2016 Jul;101(7):803-11. doi: 10.3324/haematol.2016.144428. Review.

17.

The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature.

Jethwa KD, Bishton MJ, Fox CP.

Br J Haematol. 2017 Aug;178(3):476-479. doi: 10.1111/bjh.14130. Epub 2016 May 5. Review. No abstract available.

PMID:
27146257
18.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.

PMID:
27132696
19.

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.

20.

Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.

Eyre TA, Fox CP, Shankara P, Went R, Schuh AH.

Br J Haematol. 2017 May;177(3):486-491. doi: 10.1111/bjh.14066. Epub 2016 Apr 7. No abstract available.

PMID:
27061924
21.

Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.

Bishton MJ, McMillan AK, Fox CP.

Br J Haematol. 2017 Apr;177(2):320-321. doi: 10.1111/bjh.14050. Epub 2016 Mar 28. No abstract available.

PMID:
27018322
22.

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.

Burns DM, Rana S, Martin E, Nagra S, Ward J, Osman H, Bell AI, Moss P, Russell NH, Craddock CF, Fox CP, Chaganti S.

Bone Marrow Transplant. 2016 Jun;51(6):825-32. doi: 10.1038/bmt.2016.19. Epub 2016 Feb 22.

23.

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP.

Br J Haematol. 2016 Jan;172(2):246-54. doi: 10.1111/bjh.13831. Epub 2015 Nov 18.

PMID:
26577576
24.

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.

Burns DM, Tierney R, Shannon-Lowe C, Croudace J, Inman C, Abbotts B, Nagra S, Fox CP, Chaganti S, Craddock CF, Moss P, Rickinson AB, Rowe M, Bell AI.

Blood. 2015 Dec 17;126(25):2665-75. doi: 10.1182/blood-2015-08-665000. Epub 2015 Oct 8.

25.

Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort.

Bishton MJ, Hubbard R, Witherall R, Jones SG, Richardson F, James EJ, Sovani V, Bessell EM, Haynes AP, McMillan AK, Fox CP.

Ann Oncol. 2015 Nov;26(11):2356-7. doi: 10.1093/annonc/mdv359. Epub 2015 Sep 15. No abstract available.

PMID:
26374286
26.

High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation.

Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A.

Leuk Lymphoma. 2015;56(12):3295-300. doi: 10.3109/10428194.2015.1037764. Epub 2015 Aug 26.

PMID:
25899403
27.

A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells.

Lopez-Granados E, Stacey M, Kienzler AK, Sierro S, Willberg CB, Fox CP, Rigaud S, Long HM, Hislop AD, Rickinson AB, Patel S, Latour S, Klenerman P, Chapel H.

Clin Exp Immunol. 2014 Dec;178(3):470-82. doi: 10.1111/cei.12427.

28.

Primary CNS lymphoma.

Phillips EH, Fox CP, Cwynarski K.

Curr Hematol Malig Rep. 2014 Sep;9(3):243-53. doi: 10.1007/s11899-014-0217-2. Review.

29.

Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment.

Ahearne MJ, Allchin RL, Fox CP, Wagner SD.

Br J Haematol. 2014 Aug;166(3):326-35. doi: 10.1111/bjh.12941. Epub 2014 May 12. Review.

PMID:
24815671
30.

Acute disseminated encephalomyelitis following allo-SCT: central nervous system manifestation of GVHD.

Harvey CM, Gottipati R, Schwarz S, Auer D, O'Donoghue M, Russell NH, Fox CP.

Bone Marrow Transplant. 2014 Jun;49(6):854-6. doi: 10.1038/bmt.2014.29. Epub 2014 Mar 17. No abstract available.

PMID:
24637899
31.

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, Craddock CF, Chaganti S.

Bone Marrow Transplant. 2014 Feb;49(2):280-6. doi: 10.1038/bmt.2013.170. Epub 2013 Nov 11.

PMID:
24212561
32.

EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT.

Fox CP, Bishton MJ, O'Connor S, Hughes S, Byrne JL, Russell N.

Bone Marrow Transplant. 2014 Jan;49(1):150-2. doi: 10.1038/bmt.2013.125. Epub 2013 Aug 12. No abstract available.

PMID:
23933761
33.

Epstein-Barr virus and infectious mononucleosis: what students can teach us.

Rickinson AB, Fox CP.

J Infect Dis. 2013 Jan 1;207(1):6-8. doi: 10.1093/infdis/jis647. Epub 2012 Oct 24. No abstract available.

PMID:
23100564
34.

Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.

George LC, Rowe M, Fox CP.

Curr Hematol Malig Rep. 2012 Dec;7(4):276-84. doi: 10.1007/s11899-012-0136-z. Review.

PMID:
22983913
35.

Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations.

Fox CP, Shannon-Lowe C, Rowe M.

Herpesviridae. 2011 Sep 7;2:8. doi: 10.1186/2042-4280-2-8.

36.

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M.

Blood. 2010 Nov 11;116(19):3695-704. doi: 10.1182/blood-2010-06-292268. Epub 2010 Jul 29.

37.

Immunotherapy for Epstein-Barr virus-associated malignancies.

Long HM, Parsonage G, Fox CP, Lee SP.

Drug News Perspect. 2010 May;23(4):221-8. doi: 10.1358/dnp.2010.23.4.1439500. Review.

PMID:
20520851
38.

Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells.

Fox CP, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, O'Connor N, Rowe M.

Clin Infect Dis. 2010 Jul 1;51(1):66-9. doi: 10.1086/653424.

PMID:
20504238
39.

EBV meets its match.

Fox CP, Rickinson AB.

Blood. 2010 Feb 4;115(5):920-1. doi: 10.1182/blood-2009-11-252437. No abstract available.

40.

Haematological malignancies presenting with acute liver injury: a single-centre experience.

Shetty S, Holt AP, Syn WK, Fox CP, Gunson B, Neil D, Haydon G.

QJM. 2008 Dec;101(12):949-53. doi: 10.1093/qjmed/hcn121. Epub 2008 Sep 23.

PMID:
18812406
41.

IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.

Fox CP, McMillan AK, Bishton MJ, Haynes AP, Russell NH.

Br J Haematol. 2008 Apr;141(2):244-8. doi: 10.1111/j.1365-2141.2008.07068.x.

PMID:
18353164
42.

Low dose erythropoietin is effective in reducing transfusion requirements following allogeneic HSCT.

Fox CP, Pacey S, Das-Gupta EP, Russell NH, Byrne JL.

Transfus Med. 2005 Dec;15(6):475-80.

PMID:
16359418
43.

Impact of candidate sire number and sire relatedness on DNA polymorphism-based measures of exclusion probability and probability of unambiguous parentage.

Sherman GB, Kachman SD, Hungerford LL, Rupp GP, Fox CP, Brown MD, Feuz BM, Holm TR.

Anim Genet. 2004 Jun;35(3):220-6.

PMID:
15147394

Supplemental Content

Support Center